As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: October 24, 2012
by Business Standard:
A blood pressure drug could revolutionise Alzheimer’s treatment with scientists finding in it a potential to reduce brain inflammation and prevent memory loss.
Researchers from the Imperial College London found that the drug called prazosin prevented memory loss in mice showing signs of Alzheimer’s disease.
Previous studies have shown how blood pressure drugs can prevent Alzheimer’s from occurring as well as slowing its progression, the Daily Express reported. High blood pressure is one of the known risk factors for developing Alzheimer’s.
Fast and effective communication between brain cells is essential for the normal functioning of the brain and is orchestrated by chemical messengers called neurotransmitters. The neurotransmitter noradrenaline, as well as several others, can become disrupted in particular areas of the brain during Alzheimer’s. The team set out to investigate whether drugs that affect the action of noradrenaline could provide benefits in mice showing features of Alzheimer’s.
They tested a range of compounds in the laboratory and found that the drug prazosin, which can be used to relax blood vessels in people with high blood pressure, also showed potential for reducing signs of Alzheimer’s.
The researchers then used the drug to treat mice bred to develop a build-up of the Alzheimer’s protein amyloid in their brain.
These mice showed a decline in memory performance which is characteristic of the disease in humans. The team found that treatment with prazosin could prevent the memory problems seen in untreated mice.
The drug did not reduce levels of the amyloid protein, but did appear to affect levels of inflammation in the brain. Prazosin boosted the number of brain support cells called astrocytes, which can produce anti-inflammatory proteins.
“We think the drug may stimulate an anti-inflammatory response, and there is increasing evidence that inflammation is a key process in Alzheimer’s,” Dr Magdalena Sastre, from the Department of Medicine at Imperial College London, said.
The research was published in the journal Neurobiology of Aging.
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.